PHIOGEN's CEO explains the concept of using phages against drug-resistant bacteria
An AI expert describes how machine learning is changing drug development
The CEO of NKILT Therapeutics talks about using NK cells to target the HLA-G pathway
Tvardi Threrapeutics' CEO on targeting STAT3
Everything drug developers need to know about CPRIT oncology grants
UTMB's President discusses his institution, and comments on the chronic kidney disease field
The director of Rice's Biotech Launchpad describes technologies that are being turned into companies
Texas Medical Center's CEO talks about Houston's new TMC Helix Park
BioHouston CEO Ann Tanabe kicks off the 2023 Texas Life Science Forum
Y-Trap's Rishi Bedi on how predictive & generative AI are changing drug development
Dan Chen's closing takeaways from #SITC23
Aleta Biotherapeutics' Paul Rennert on what he sees is working, and what isn't, at #SITC23
The CEO of Marengo Therapeutics talks about his company's focus on activating and expanding T-cells
Parker Institute for Cancer Immunotherapy's John Connolly on what he is seeing at #SITC23
SITC Biotech Strategic Initiative Co-Chair Kristen Hege on the IO field
Mizuho Senior Analyst Mara Goldstein gives a preview of #SITC23
Capstan Therapeutics' Laura Shawver on 'decorating' LNPs with antibodies
Dr. Eric Topol on the latest advances in medicine
Antibody oligonucleotide conjugates as an RNA strategy with the CEO of Avidity Biosciences
Breakfast at biolabs: Dallas Regional Chamber
.png){kind=logo}
